Efficacy and Safety of Aumolertinib With or Without Chemotherapy as First-line Treatment in Locally Advanced or Metastatic Non-Small Cell Lung Cancer With Sensitizing Epidermal Growth Factor Receptor Mutations: A Randomized, Controlled, Open-label, Phase 3 and Multicenter Clinical Study
Latest Information Update: 12 Jun 2023
At a glance
- Drugs Aumolertinib (Primary) ; Carboplatin; Cisplatin; Pemetrexed
- Indications Non-small cell lung cancer
- Focus Registrational; Therapeutic Use
- Sponsors Jiangsu Hansoh Pharmaceutical
- 08 Jun 2023 Status changed from not yet recruiting to recruiting.
- 16 Jun 2021 New trial record